Sign In
Buy ATS
$28.85
-1.01 (-3.38%)
At Close: Jun 03, 2026
ATS Corporation (ATS:CA) Q4 2026 Earnings Call Transcript
12:44pm, Thursday, 28'th May 2026
ATS Corporation (ATS:CA) Q4 2026 Earnings Call Transcript
ATS Q4 Earnings Call Highlights
12:10pm, Thursday, 28'th May 2026
ATS NYSE: ATS reported higher fiscal 2026 revenue and adjusted earnings from operations, while outlining a series of restructuring actions aimed at improving margins, cash generation and capital effic
ATS (ATS) Q4 Earnings Lag Estimates
08:16am, Thursday, 28'th May 2026
ATS (ATS) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.28 per share a year ago.
ATS Reports Fourth Quarter Fiscal 2026 Results
06:00am, Thursday, 28'th May 2026
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today reported its financial results for the three and twelve months ended March 31, 2026. All referen
On May 20, 2026, Nordson Corp (NDSN) released its 8-K filing reporting record second-quarter fiscal 2026 results. Sales reached $741 million, up 8% year over ye
Securitize Reports First Quarter 2026 Results
11:00am, Wednesday, 20'th May 2026
Securitize Reports First Quarter 2026 Results PR Newswire MIAMI, May 20, 2026 MIAMI
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 Internati
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
03:00pm, Sunday, 17'th May 2026
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being present
ATS to Host Fourth Quarter Earnings Call Thursday May 28, 2026, at 8:30 a.m. Eastern
05:00pm, Thursday, 14'th May 2026
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the fourth quarter ended March 31, 2026, before marke
Genpact Declines 9.4% Since Beating Q1 Earnings & Revenue Estimates
01:10pm, Wednesday, 13'th May 2026
G's shares fall 9.4% despite Q1 results beating estimates. Weak Q2 revenue guidance overshadows strong AI-led ATS growth.
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
04:05pm, Monday, 11'th May 2026
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyse
Celestica Surpasses Q1 Earnings Estimates on Solid CCS Demand
10:47am, Tuesday, 28'th Apr 2026
CLS beats Q1 estimates as CCS revenue jumps 76% and margins expand. Management lifts 2026 revenue and EPS outlook.
Will ATS (ATS) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Monday, 27'th Apr 2026
ATS (ATS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ATS (TSE:ATS) Trading Down 3.2% – What’s Next?
02:19am, Saturday, 25'th Apr 2026
ATS Co. (TSE: ATS - Get Free Report)'s share price traded down 3.2% on Friday. The company traded as low as C$45.17 and last traded at C$45.17. 156,131 shares were traded during mid-day trading, a dec
